13F Holdings
中文EN

CORT CORCEPT THERAPEUTICS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1088856 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY30.0%
TTM net income YoY52.9%
TTM EPS YoY52.9%
Revenue 3-yr CAGR28.9%
Net income 3-yr CAGR21.1%

Margins

Gross margin98.5%
Operating margin11.5%
Net margin16.8%
FCF margin20.2%
EBITDA margin11.8%

Returns

ROE22.1%
ROA17.5%
ROIC (approx.)17.9%
Asset turnover1.04x

Leverage & solvency

Liabilities / assets19.4%
Debt / equity0.00x
Current ratio3.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.22x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$340.47M$256.15M$164.90M$202.12M$207.64M$194.43M$157.21M$181.89M
Cost of revenue$4.61M$4.06M$2.88M$2.54M$4.60M$3.43M$2.40M$2.96M
Gross profit$335.86M$252.09M$162.02M$199.58M$203.04M$191.00M$154.81M$178.93M
R&D expense$56.71M$53.89M$66.27M$64.86M$68.85M$60.47M$60.73M$70.30M
SG&A expense$164.43M$156.90M$145.36M$130.24M$123.98M$103.85M$90.66M$83.37M
Operating income$114.72M$41.30M-$49.60M$4.49M$10.22M$26.68M$3.42M$25.26M
Pretax income$120.31M$45.93M-$44.72M$9.91M$15.24M$31.69M$9.62M$31.96M
Income tax-$6.47M$2.94M-$12.95M-$14.38M-$4.42M-$3.46M-$10.93M$1.21M
Net income$126.78M$42.99M-$31.76M$24.29M$19.67M$35.15M$20.55M$30.75M
EBITDA$115.75M$42.16M-$49.00M$4.78M$10.70M$27.14M$3.88M$25.54M
EPS (basic)1.170.40-0.30—0.190.330.19—
EPS (diluted)1.010.36-0.30—0.160.290.17—
Weighted avg. shares (diluted)123.20M118.39M104.44M—119.44M120.48M119.82M—
Balance sheet
Cash & equivalents$98.72M$111.04M$108.74M$120.50M$125.14M$102.75M$89.82M$128.66M
Short-term investments$271.98M$197.16M$229.45M$251.66M$296.55M$239.48M$232.94M$255.67M
Receivables$111.06M$76.92M$39.07M$59.79M$69.63M$64.57M$61.82M$53.98M
Inventory$11.91M$13.19M$12.89M$12.87M$12.35M$12.28M$14.37M$12.41M
Current assets$533.87M$439.68M$426.03M$485.46M$541.13M$443.11M$438.50M$471.60M
PP&E, net$4.94M$5.13M$3.17M$1.89M$2.09M$2.35M$2.54M$2.69M
Total assets$1.03B$888.70M$814.88M$836.65M$823.61M$801.72M$846.46M$840.55M
Current liabilities$177.68M$153.80M$149.19M$166.09M$172.26M$144.66M$143.07M$140.77M
Total liabilities$200.29M$182.93M$176.89M$188.85M$191.71M$165.93M$163.17M$160.96M
Shareholders' equity$833.74M$705.78M$637.99M$647.80M$631.90M$635.79M$683.28M$679.59M
Shares outstanding———105.97M———105.11M
Cash flow statement
Operating cash flow$142.89M$33.54M-$16.77M$38.45M$54.48M$43.94M$4.77M$60.06M
Capital expenditure$709,000$2.53M$201,000$50,000$0$57,000$104,000$121,000
Free cash flow$142.18M$31.02M-$16.97M$38.40M$54.48M$43.88M$4.67M$59.94M
Investing cash flow-$131.99M-$29.24M$4.54M-$11.84M$14.64M$70.13M-$3.17M-$64.36M
Financing cash flow-$23.89M-$2.04M$760,000-$31.22M-$46.41M-$102.93M-$39.80M-$4.56M
Depreciation & amortization$1.03M$863,000$598,000$289,000$477,000$469,000$462,000$281,000
Stock-based compensation$29.44M$29.42M$23.04M$20.77M$22.88M$19.02M$21.83M$16.80M
Share buybacks$5.75M$0$0$0$42.46M$103.02M$27.43M$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.